Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jaut.2014.03.002 http://scihub22266oqcxt.onion/10.1016/j.jaut.2014.03.002 24703438!ä!24703438 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Autoimmun 2014 ; 50 (ä): 135-41 Nephropedia Template TP {{tp|p=24703438|t=2014. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener s) Results of a single-center cohort study on 66 patients |pdf=|usr=}}{{24703438}} gab.com Text Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener s) Results of a single-center cohort study on 66 patients JO: J Autoimmun http://www.kidney.de/pget.php?&tw=1&pmid=24703438 #FOAvip The aim of this study was to evaluate the efficacy and safety of rituximab (RTX) associated with glucocorticoid treatment based on disease severity, as a remission induction treatment for granulomatosis with polyangiitis (GPA) (Wegener's) and to analyze the results of long-term maintenance therapy with low doses of RTX in a routine time-based protocol. This single-center retrospective study used standardized data collection from all GPA patients receiving RTX between 2002 and 2013. The remission induction regimen consisted of RTX and glucocorticoids, adapted according to disease severity. Once remission was achieved, patients received RTX maintenance treatment (500 mg every 6 months) for 18 months. Sixty-six GPA patients received RTX for remission induction. After six months, a response had been achieved in 78.8% of these patients, with a moderate oral prednisone regimen (mean dose at baseline, 32.8 +/- 23.4 mg/day). Subglottic stenosis increased the risk of treatment failure (OR = 31.2, P = 0.0104). RTX maintenance treatment was continued for 18 months in 92% of the GPA patients, who were followed for 34.2 +/- 26.2 months (mean total cumulative RTX dose of 4.6 +/- 1.7 g). The relapse rate was 11.2/100 patient-years. The relapses occur a mean of 13.5 +/- 14.7 months after the last RTX infusion. Twenty-one severe adverse events were recorded; 13.6% patients had severe infections. We conclude that in this single-center cohort, RTX associated with glucocorticoid treatment adapted for disease severity appeared to induce remission effectively in GPA patients. Maintenance treatment with low doses of RTX in a routine time-based protocol was safe and associated with low rates of relapse on treatment. Twit Text FOAVip Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener s) Results of a single-center cohort study on 66 patients ????J Autoimmun http://www.kidney.de/pget.php?&tw=1&pmid=24703438 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24703438 #FOAvip English Wikipedia <ref>{{Cite pmid|24703438}}</ref> Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener s) Results of a single-center cohort study on 66 patients #MMPMID24703438 Calich AL; Puechal X; Pugnet G; London J; Terrier B; Charles P; Mouthon L; Guillevin L J Autoimmun 2014[May]; 50 (ä): 135-41 PMID24703438show ga The aim of this study was to evaluate the efficacy and safety of rituximab (RTX) associated with glucocorticoid treatment based on disease severity, as a remission induction treatment for granulomatosis with polyangiitis (GPA) (Wegener's) and to analyze the results of long-term maintenance therapy with low doses of RTX in a routine time-based protocol. This single-center retrospective study used standardized data collection from all GPA patients receiving RTX between 2002 and 2013. The remission induction regimen consisted of RTX and glucocorticoids, adapted according to disease severity. Once remission was achieved, patients received RTX maintenance treatment (500 mg every 6 months) for 18 months. Sixty-six GPA patients received RTX for remission induction. After six months, a response had been achieved in 78.8% of these patients, with a moderate oral prednisone regimen (mean dose at baseline, 32.8 +/- 23.4 mg/day). Subglottic stenosis increased the risk of treatment failure (OR = 31.2, P = 0.0104). RTX maintenance treatment was continued for 18 months in 92% of the GPA patients, who were followed for 34.2 +/- 26.2 months (mean total cumulative RTX dose of 4.6 +/- 1.7 g). The relapse rate was 11.2/100 patient-years. The relapses occur a mean of 13.5 +/- 14.7 months after the last RTX infusion. Twenty-one severe adverse events were recorded; 13.6% patients had severe infections. We conclude that in this single-center cohort, RTX associated with glucocorticoid treatment adapted for disease severity appeared to induce remission effectively in GPA patients. Maintenance treatment with low doses of RTX in a routine time-based protocol was safe and associated with low rates of relapse on treatment. |Adult[MESH] |Aged[MESH] |Antibodies, Monoclonal, Murine-Derived/*therapeutic use[MESH] |Drug Administration Schedule[MESH] |Drug Monitoring[MESH] |Drug Therapy, Combination[MESH] |Female[MESH] |Glucocorticoids/*therapeutic use[MESH] |Granulomatosis with Polyangiitis/*drug therapy/immunology/pathology[MESH] |Humans[MESH] |Immunologic Factors/*therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Prednisone/*therapeutic use[MESH] |Recurrence[MESH] |Remission Induction[MESH] |Retrospective Studies[MESH] |Rituximab[MESH]Rituximab for induction and maintenance therapy in granulomatosis with(epmc).pdf DeepDyve Pubget Overpricing